Identification of novel mutations of Insulin Receptor Substrate 1
(IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications foraberrant insulin signaling in development of cancer. This evidence concerns the gene INS and non-small cell lung carcinoma.